Pricing Log in Create free account

Neuphoria Therapeutics Inc. (NEUP) vs TScan Therapeutics, Inc. (TCRX)

Neuphoria Therapeutics Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Neuphoria Therapeutics Inc. is the larger, with a market value of $17.9M against $16.2M — 1.1× the size. Neuphoria Therapeutics Inc. grew revenue faster over the last twelve months: 3,535.1% against 2.15%. Neuphoria Therapeutics Inc. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (−232.7% vs −4,588.2%). Across the 19 metrics below, Neuphoria Therapeutics Inc. leads on 13 and TScan Therapeutics, Inc. on 6.

Valuation

Metric NEUP TCRX Biotechnology median
P/E n/m n/m 8.50
P/S 0.91 4.20 9.71
P/B 0.58 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.27 0.32 0.64
EV/Sales (0.30) (5.27) 9.21
Earnings yield (154.60%) (395.65%) (33.15%)
Free cash flow yield (85.14%) (396.18%) (25.50%)

Profitability

Metric NEUP TCRX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity (61.70%) (95.80%) (56.36%)
Return on assets (46.95%) (50.09%) (48.04%)
Return on invested capital (232.67%) (4,588.23%) 0.00%

Growth

Metric NEUP TCRX Biotechnology median
Revenue growth (TTM) 3,535.05% 2.15% 6.02%
EPS growth (last fiscal year) (1,230.43%) 12.28% 30.26%
Revenue growth, 5-year CAGR 19.07% 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NEUP TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 27.85 3.37 4.72
Net debt to EBITDA 1.26 0.90 0.96

Dividend

Metric NEUP TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NEUP TCRX Biotechnology median
Market cap 17.91m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack